Liver follicular helper T-cells predict the achievement of virological response following interferon-based treatment in HCV-infected patients

Antiviral Therapy

Volumn 17, Issue 1, 2012, Pages 111-118

  Tripodo, Claudio ^a   Petta, Salvatore ^a   Guarnotta, Carla ^a   Pipitone, Rosaria ^a   Cabibi, Daniela ^a   Colombo, Mario P ^b   Craxi, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ADULT; AGE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FIBROSIS; GENETIC POLYMORPHISM; GENOTYPE; HELPER CELL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SEX; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BIOMARKERS, PHARMACOLOGICAL; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; INTERLEUKINS; LIVER; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; T-LYMPHOCYTES, HELPER-INDUCER; VIRAL LOAD;

EID: 84856158421     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1957     Document Type: Article

References (22)

1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
2. Bruno S, Cammà C, Di Marco V, et al. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 2004; 41:474-481. (Pubitemid 39158756)
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
4. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
5. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferonalpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
6. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135:451-458.
7. Thimme R, Oldach D, Chang KM, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194:1395-1406. (Pubitemid 33081515)
8. Shirakawa H, Matsumoto A, Joshita S, et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008; 48:1753-1760.
9. Masaki N, Fukushima S, Hayashi S. Lower th-1/th-2 ratio before interferon therapy may favor long-term virological responses in patients with chronic hepatitis C. Dig Dis Sci 2002; 47:2163-2169.
10. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008; 112:1557-1569.
11. King C. New insights into the differentiation and function of T follicular helper cells. Nat Rev Immunol 2009; 9:757-766.
12. Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG. Follicular helper T cells: lineage and location. Immunity 2009; 30:324-335.
13. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419. (Pubitemid 15018832)
14. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372-374.
15. Tripodo C, Di Bernardo A, Ternullo MP, et al. CD146(+) bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis. Haematologica 2009; 94:127-130.
16. EASL International Consensus Conference on Hepatitis C Paris, 26-27 February 1999 Consensus Statement. J Hepatol 1999; 31 Suppl 1:3-8.
17. Cucak H, Yrlid U, Reizis B, et al. Type I interferon signaling in dendritic cells stimulates the development of lymphnode-resident T follicular helper cells. Immunity 2009; 31:491-501.
18. Reinhardt RL, Liang HE, Locksley RM. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat Immunol 2009; 10:385-393.
19. Jordan WJ, Eskdale J, Srinivas S, et al. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun 2007; 8:254-261. (Pubitemid 46679436)
20. Yusuf I, Kageyama R, Monticelli L, et al. Germinal center T follicular helper cell IL-4 production is dependent on signaling lymphocytic activation molecule receptor (CD150). J Immunol 2010; 185:190-202.
21. Megjugorac NJ, Gallagher GE, Gallagher G. IL-4 enhances IFN-lambda1 (IL-29) production by plasmacytoid DCs via monocyte secretion of IL-1Ra. Blood 2010; 115:4185-4190.
22. Spolski R, Leonard WJ. IL-21 and T follicular helper cells. Int Immunol 2010; 22:7-12.